Shan Xiaoting, Gong Xiang, Li Jie, Wen Jingyuan, Li Yaping, Zhang Zhiwen
State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
School of Pharmacy, University of Chinese Academy of Sciences, Beijing 100049, China.
Acta Pharm Sin B. 2022 Jul;12(7):3028-3048. doi: 10.1016/j.apsb.2022.02.025. Epub 2022 Mar 1.
Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review provides a snapshot of nanomedicines that have been currently launched or in the clinical trials, which manifests a diversified trend in carrier types, applied indications and mechanisms of action. From the perspective of indications, this article presents an overview of the applications of nanomedicines involving the prevention, diagnosis and treatment of various diseases, which include cancer, infections, blood disorders, cardiovascular diseases, immuno-associated diseases and nervous system diseases, etc. Moreover, the review provides some considerations and perspectives in the research and development of nanomedicines to facilitate their translations in clinic.
与传统药物疗法相比,纳米药物展现出引人入胜的生物学特性,可提高治疗效果、降低毒性并实现靶向递送。本综述概述了目前已上市或正在进行临床试验的纳米药物,这些药物在载体类型、应用适应症和作用机制方面呈现出多样化的趋势。从适应症的角度来看,本文概述了纳米药物在各种疾病的预防、诊断和治疗中的应用,包括癌症、感染、血液疾病、心血管疾病、免疫相关疾病和神经系统疾病等。此外,本综述还提供了纳米药物研发中的一些考虑因素和观点,以促进其临床转化。